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ABSTRACT
Fragile X Syndrome (FXS) is an X-linked disorder characterized by a CGG
trinucleotide repeat located within the 5’ untranslated region of the Fragile X Mental
Retardation 1 gene (FMR1). The FMR1 gene is further categorized into classifications of
protein function such as normal, intermediate, premutation or full mutation depending on
the number of CGG repeats present23. A normal FMR1 gene exhibits anywhere between 5
and 44 repeats. An allele in intermediate range displays 45-54 repeats. A premutation allele
occurs when 55-200 CGG repeats are present and levels of the FMR1 gene product, Fragile
X Mental Retardation Protein (FMRP) start to deplete. When alleles fall into this range,
they are subject to expansion when transmitted into subsequent generations. Additionally,
female premutation carriers are at risk for inheriting Fragile X-associated Primary Ovarian
Insufficiency (FXPOI), which causes the ovaries to not work correctly. A full mutation
displays complete methylation of the FMR1 gene, no FMRP production, and greater than
200 repeats. An individual diagnosed with a full mutation for FXS exhibits developmental
and behavioral issues that include, but are not limited to, intellectual impairment, failure to
meet milestones, and lack of impulse control20.
Due to the severity of a full mutation of FXS, and risk of FXPOI and expansion,
female patients seek reproductive assistance from infertility specialists. A current method
of testing for FXS involves the use of quantitative Polymerase Chain Reaction (qPCR)based single nucleotide polymorphism (SNP) genotyping for linkage analysis. The
inheritance pattern of the affected allele is tracked throughout this process; however, the
number of repeats present is not observed. This project aims to establish a method for
detecting Fragile X CGG repeats within embryo trophectoderm (TE) biopsies. The
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determination of CGG repeats is a crucial addition to current methods of testing to avoid
the risk of expansion and to assist patients in obtaining a healthy pregnancy12.
This study was broken down into the completion of four phases. It began with the
validation of Asuragen’s Amplidex PCR/CE FMR1 reagent kit to detect CGG repeats
within the FMR1 gene of genomic DNA (gDNA) samples. The use of gDNA with this kit
served as a gold standard for comparisons throughout this project. The next phase
included, cell lines with known CGG repeat sizes to mimic TE biopsies. They were then
tested on four different amplification methods. Those methods included GenomePlex
WGA4, SurePlex DNA, REPLI-g Single Cell Kit, and targeted pre-amplification. Next,
arrested whole embryos were used to test the ability of the chosen amplification method
on embryonic samples. Lastly, TE biopsies from discarded aneuploid whole embryos to
observe the developed methodology’s accuracy on clinical samples.
The gDNA results were as expected and provided a source for the validation of
this methodology. Although three out of the four amplification methods being tested did
not provide usable results, the REPLI-g Single Cell Kit showed very promising results. It
showed 100% consistency with the expected results from the cell lines used. This
amplification method was then used on arrested whole embryos and showed CGG repeat
sizes as expected from parental genotypes. The TE biopsies showed encouraging results,
suggesting that this procedure has potential for clinically implementation.
CGG repeat sizes and expansion can be observed using this new methodology. It
has the potential application to assess the amount of expansion for patients with limited
numbers of usable embryos. Transferring embryos with FMR1 premutation alleles will
encompass more diligent genetic counseling and detailed consents.
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INTRODUCTION
Infertility affects approximately 15% of the reproductive aged population. It is
defined as the inability to conceive a clinical pregnancy after one year of unprotected
intercourse and can affect both males and females1. Causes of infertility in males can be
due to hormonal imbalances, genetic disorders, or disruption of the testicular and
ejaculatory functions. Additionally, females experience issues with fertility due to
disruption of ovarian function from genetic disorders, obstruction of the fallopian tubes,
and abnormal uterine contour2. Assisted reproductive technologies (ART) are used to
treat infertility and contribute to increased delivery rates. Over the past few decades,
advances of ART continuingly increased, with the most effective treatment option being
in-vitro fertilization (IVF). IVF is a process in which ova are retrieved from the ovaries of
the female patient; while simultaneously, a sperm sample from the male partner is
collected. The ovum is then fertilized in-vitro and transferred into the uterus of the female
patient3. Although seemingly effective, there are still limitations that are involved with
the use of IVF. The failure of embryos to implant is a main concern for reproductive
specialists.
There are many possible explanations why embryos fail to implant; such as,
uterine environment, embryo quality, the age of the egg retrieved, or chromosomal
abnormalities4. All embryos are expected to inherit forty-six chromosomes; twenty-three
from each the contributing mother and father. When an embryo exhibits the correct
number of chromosomes it is referred to as euploid; while an embryo that displays an
incorrect number of chromosomes is considered aneuploid. Aneuploidy is likely the most
prevalent cause for the formation of genetic abnormalities and the leading genetic cause
9

of miscarriages5,6. There is an aberrant chromosomal segregation that occurs; which
results in an abnormal number of chromosomes inherited by the embryo7. A previous
study collected data to support the notion that aneuploidy, additionally, increases with
maternal age8. This is problematic for reproductive specialists as they counsel women in
pursuit of IVF. They observed a steady increase of aneuploidy observed within the
embryos of female patients above the age of 30. Furthermore, the same cohort of women
are at risk for having little to no euploid embryos available for transfer8.
To overcome the limitations of IVF, researchers developed technologies used
currently in clinical practice to assist in the evaluation of human embryos during the IVF
process. Preimplantation genetic diagnosis (PGD) of aneuploidy significantly reduces the
risk of delivering a chromosomally abnormal offspring9. PGD is a process in which a
biopsy of 5-10 cells is taken from the trophectoderm (TE) of the blastocyst stage embryo
and chromosome copy number is determined prior to transfer back into the female
patient’s uterus. It has been established that blastomere biopsies on day 3 embryos during
the cleavage stage had a significant reduction in sustained implantation. However, most
clinics conduct biopsies from the TE of a day 5 or 6 blastocyst, which showed to be
comparative to controls with no statistical difference between the sustained implantation
rates9.
The recent developments of comprehensive chromosome screening (CCS), a form
of PGD, have been validated and clinically implemented to assess chromosome copy
number of all 24 chromosomes (chromosomes 1-22, X and Y)10. Quantitative Polymerase
Chain Reaction (qPCR) based methods of CCS are the most efficient in respect to
experimental time and analysis11. In 2004, Handyside et al isolated small quantities of
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genomic DNA (gDNA) from cleavage stage embryos that underwent whole genome
amplification (WGA) to produce microgram quantities of amplified DNA. This DNA was
used for PGD using a qPCR based method for chromosome screening11. Although
effective, there were some limitations using WGA. Allele drop out (ADO) occurs and
amplification failure occurs frequently with the use of WGA12. ADO occurs when one or
both alleles of a heterozygote fail to amplify. Additionally, the primers anneal randomly
and cause only about 60% of the inputted DNA to be amplified. Due to these limitations,
Zimmerman et al focused on constructing a technology that did not need to assistance of
whole genome amplification12. Successfully, Zimmerman and her group developed and
validated a platform for simultaneous chromosome screening and single gene disorder
(SGD) testing12. qPCR can provide additional genotypic information that is useful for
detecting, and diagnosing many SGD’s13. Currently, many groups shifted focus towards
the use of next generation sequencing as standard CCS method. The use of targeted next
generation sequencing (tNGS) has been recently validated by Zimmerman et al as a more
advanced and efficient method of CCS; however, it is not yet been established to work
for SGD testing14.
In 2015, Werner et al conducted a study to clarify the accuracy of CCS using
PCR-based methodologies and how they affected implantation and delivery rates. The
researchers observed equivalent accuracy to commonly used CCS techniques, increased
throughput, and simultaneous detection of SGD’s12,15. The list of different SGD’s that are
commonly tested for is extensive; however, one specific disorder commonly tested for
among infertility clinics is Fragile X Syndrome (FXS).
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FXS is the most inherited form of mental retardation and affects about 1 in every
4000 males and 1 in every 8000 females16. FXS can be characterized by a tri-nucleotide
CGG repeat within the 5’ untranslated region (UTR) of the Fragile X Mental Retardation
1 (FMR1) gene. The FMR1 gene exists in four different allelic forms. The first is a
normal FMR1 allele, that exhibits less than 45 CGG repeats and paired with normal
production of the FMR1 gene product; Fragile X Mental Retardation Protein (FMRP)17.
The next allelic form is an intermediate, or gray zone, FMR1 allele. These alleles display
between 45 and 55 CGG repeats with normal FMRP production. The next form is a
premutation FMR1 allele, which exhibits between 55 and 200 CGG repeats17. When an
allele reaches this range the levels of FMRP start to deplete. Individuals with alleles that
fall into these first three ranges display between 0 and 3 AGG interruptions. These
interruptions create stability for the gene by revealing an AGG approximately every 9 or
10 CGG repeats17. The fourth and final allele form is a full mutation FMR1 allele. A full
mutation allele exhibits greater than 200 CGG repeats and complete methylation (the
addition of a methyl group to the CpG islands) of the 5’ UTR of the FMR1 gene. In turn,
this causes transcriptional silencing and no FMRP production16.
FXS demonstrates an x-linked inheritance pattern16. The first observation of a
variant X chromosome, that was associated with intellectual disabilities, was used as a
marker X chromosome to gain knowledge about X linkage inheritance18. These
researchers determined that the expression of a chromosomal variant may vary from
generation to generation. To go into further detail, Martin et al’s group developed the first
pedigree describing inheritance patterns of mental defects caused by sex linkage19. For
example, when females are carriers of FXS, their offspring will have a 50% chance of
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inheriting the affected X chromosome. Comparatively, male carriers will always pass on
their affected X chromosome to their daughter9.
When an individual expresses a full mutation FMR1 allele, they exhibit a variety
of phenotypic indicators. There is the presence of a fragile site at Xq27.320,21 and displays
of moderate to severe mental retardation16,20. Penetrant males of FXS almost always
display severe intellectual disabilities; or mental retardation. They are also subject to
abnormal facial features such as large ears, prominent jaw, and macroorchidism. Other
complications, such as anxiety, hyperactivity, and autism-like behaviors, also accompany
the previously discussed list of phenotypes. Females are likely to have more mild forms
of mental retardation and variable accompanying physical, or psychiatric, features16,2.
This is due to the mutation being x-linked and females undergoing the process of xinactivation. It has been established that FMR1 expression does not occur from the
inactive X chromosome; therefore, is subject to X chromosome inactivation23.
The lack of FMRP consequently causes the expression of the previously described
phenotypic indicators. FMRP is a ribonucleic acid (RNA) binding protein24. It is part of a
ribonucleoprotein complex responsible for translating polyribosomes, which can travel
between the cytoplasm and the nucleus of a cell. It is known and well established that
FMRP is involved in nuclear export, cytoplasmic transference, and/or translational
control of specific messenger RNA (mRNA) molecules. It is suggested by Bardoni et al
to play a role in the regulation of protein synthesis at the dendrite postsynaptic sites of
neurons within the brain24. In particular, FMRP is accountable for the maturing of
dendrite spines, which receive sensory input and transmit electrical signals to the neurons
cell body. These structures of the neuron play important roles in motivation, learning25,
13

and memory6. FMRP is suggested to play a role in the maintenance of memory over a
lifespan because long-term memory is facilitated by the growth of dendritic spines, or
elongation of existing spines. Therefore, when there is an absence of FMRP, the dendrite
spines experience complications with their maturation process leading memory and
learning abilities to be affected27. FMRP is also found to play a role in the development
of the reproductive organs and can cause severe issues with fertility, especially in
womenError! Bookmark not defined.7,24.
The slow depletion of FMRP when a FMR1 allele falls within the premutation
range is paired with an increase of FMR1 mRNA transcripts. It is still unclear how this
mechanism occurs; however, there are some theories28. There is a hypothesis suggested to
explain the paradox of increased FMR1 transcripts unexpectedly associated with
decreased levels of FMRP. This theory suggests that the increased number of CGG
repeats leads to the translational inhibition of the FMR1 transcripts by causing
conformational changes of the transcripts themselves. This conformational change in the
FMR1 transcript impacts the commencement of translation and hinders the 40S
ribosomal subunits evidently causing the reduced production of FMRP28.
Fertility becomes problematic specifically for FMR1 permutation carries.
Premutation FMR1 alleles attributes to a spectrum of different phenotypic indicators
depending on the CGG repeat length2. Clinically significant phenotypes and risks are
suggested to have a positive correlation with the increase of the CGG repeat size; which
plateaus around 100 repeats for alleles within this range. Premutation carriers are at risk
for inheriting other Fragile X associated disorders, including fragile X tremor/ataxia
syndrome (FXTAS)29. FXTAS most commonly affects males; however, females can
14

inherit this disorder as well. FXTAS is a neurodegenerative disorder characterized by
late-onset of progressive cerebellar ataxia and tremors. It is also associated with shortterm memory loss, executive function deficits, cognitive decline, muscle weakness and
autonomic dysfunction to name a few symptoms9. Another Fragile X associated disorder
is Fragile X Primary Ovarian Insufficiency (FXPOI), which only affects female
premutation carriers. FXPOI is a disorder in which the ovaries do not function properly
and is defined as the cessation of menses before the age of 40 years old22. Females
affected by this disorder need assistance in reproducing; such as seeking the use of IVF.
Additional to the risk of FXPOI, premutation carriers have molecular
modifications to be cautious of as well. As an allele reaches the premutation range of 55
to 200 CGG repeats, the gene becomes remarkably unstable and is at risk to undergo
expansion during transmissions into subsequent generations8. This instability is
influenced by multiple factors. The first factor includes the ability of these repeats to
expand to a full mutation, exclusively when transmission involves a maternal premutation
allele. Although expansion from a premutation allele to a full mutation allele does not
occur in every case, an expansion to a full mutation have been documented as low as 56
CGG repeats30. In contrast, when the paternal allele is transmitted to their daughters the
allele may either expand, contract, or remain unchanged31. The second influential factor
is that the level of instability is correlated with CGG repeat size. The larger the number of
repeats being carried, allows for a greater risk of expansion. The last associated factor is
the disappearance of the AGG interruptions that are present in the normal range
population32. Typically, premutation alleles have either none or one AGG interruption
towards the 5’ end of the repeats and long uninterrupted CGG repeats towards the 3’ end.
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These are the main factors that influence the instability of premutation alleles and what
makes the transmission of these alleles worrisome for female and male carriers.
The assistance needed by female premutation carriers at risk for FXPOI and the
associated risk of expansion of premutation alleles collectively classify the importance
for IVF in reproduction. Female patients attend infertility clinics to gain insight on their
probability of conceiving a healthy offspring. Throughout the IVF process, these patients
must elect to have their embryos undergo PGD testing to ensure their optimal health.
PGD for FXS is done concurrently with qPCR-based aneuploidy screening to evaluate
the chromosome copy number of the biopsied embryo. To assess the inheritance of the
affected allele, qPCR-based SNP genotyping for linkage analysis is utilized. This method
of testing was developed and validated by Zimmerman et al in 201612. This technique
enables researchers to determine which embryos inherited the fragile X (FX) affected
chromosome by tracking linked markers. These linked markers are chosen based on the
genotypes of the informative SNPs determined by microarray of the patient and partner’s
gDNA. An informative SNP is when the mother is heterozygous and father is
homozygous. A chromosome is labeled as affected if there is the presence of an
intermediate, premutation, or full mutation FMR1 allele (or greater than 45 repeats).
Therefore, if an embryo inherited the affected X chromosome, that embryo is marked as
‘not recommended for transfer’ without determination of the CGG repeat size within the
biopsy and is then discarded. Without the repeat sizes, there is a significant amount of
embryos discarded, when in fact they may be able to produce a viable pregnancy.
Asuragen’s Amplidex PCR/CE FMR1 Reagants Kit was created by Asuragen’s
research and development department to provide reduced complexity and an optimized
16

workflow to produce a more sensitive method for determining CGG repeat sizes. There
are two PCR methods: a gene specific PCR and CGG repeat primed (RP) PCR. The gene
specific PCR involves the use of the FMR1 forward primer and the FMR1 reverse primer
and simply displays the gene specific peaks when analyzed. The use of a three-primer
CGG RP PCR on gDNA was established by Liangjing Chen from the Asuragen team33.
The development of this kit helped created the idea to pursue this project and to alter the
current protocol for testing TE biopsies for FXS. The CGG RP PCR was chosen for this
study and is distinguished for two reasons33. The first, it includes 3 primers: FMR1
forward primer and the FMR1 reverse primer to flank the FMR1 gene, and a CGG
primer. The CGG primer anneals to each CGG repeat. When the data is analyzed, one can
determine zygosity because each CGG repeat will be detected. The presence of CGG RP
peaks in the display plot provided by the analysis program communicates that there is the
presence of a longer gene specific peak. If a homozygous female was tested with 30 CGG
repeats on each chromosome, then there will be one gene specific peak present in the
normal range and no CGG primed peaks after the detection of the first gene specific peak.
The second reason is this PCR method is able to show the presence of the AGG
interruptions. Gaps will represent the AGG interruptions when each CGG RP peak is
displayed33. An obstacle with this kit is to adapt this workflow to be usable with TE
biopsies; which contain limited amount of DNA to start with. One main goal of this
project is to significantly lower the number of embryos that get discarded, when they may
in fact be able to produce a successful pregnancy. Diverging from their qPCR-based SNP
genotyping for linkage analysis and developing a more accurate method for testing these
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biopsies for FXS could be useful for physicians when counseling their female patients as
well.
Along with the risk for FXPOI, females of advanced maternal age would also
greatly benefit from a testing that offers CGG repeat sizes. These older females may only
produce one or two good-quality embryos. For example, if a woman of 42 years of age is
a premutation carrier of FXS, produces one euploid blastocyst that inherited the FX
affected haplotype and another aneuploid blastocyst that inherited a normal X
chromosome, a physician would not recommend the transfer of either embryo. Therefore,
both embryos get discarded and the woman is unable to try for a sustainable pregnancy.
However, with a newly developed test using Asuragen’s Amplidex PCR/CE FMR1
Reagant kit can provide the CGG repeat size of that euploid embryo the female patient
had available. If her premuation did not expand, the embryo would be feasible for
transfer and be at risk for very limited FX symptoms if the premutation has few CGG
repeats.
Overall, the addition of the Asuragen Amplidex PCR/CE FMR1 Reagent kit into
the clinic’s protocol for testing embryo TE biopsies can help physicians, as well as
patients. The physicians will be able to counsel patients more accurately about the
potential risks of FXS and provide more detailed information about their embryos being
tested. While the patients can benefit by potentially saving some embryos from being
discarded by using this more accurate methodology. If the test results comes back that the
CGG repeat size has not expanded, the physicians can recommend it usable for a transfer.
Therefore, giving the patient the opportunity for a sustained pregnancy and a healthy
offspring as a result. This project aims to adapt this new protocol to the already existing
18

procedures by testing different amplification methods’ accuracy along with the Asuragen
Amplidex PCR/CE FMR1 Reagent kit to determine which provides the most accurate and
reliable results for TE biopsies.
MATERIALS AND METHODS
Phase 1:
Genomic DNA isolation
Three different sample types were used when extracting gDNA. Bloodwork,
buccal swabs, or chorionic villi samples were all taken from female patients seeking IVF
treatment for FXS.
Bloodwork
Blood was drawn from IVF patients seeking SGD treatment for FXS. gDNA was
isolated using the epMotion 5075, following the protocol as recommended by Eppendorf
(Eppendorf, Mount Laurel, NJ, USA). The gDNA was quantified using a Nanodrop 8000
spectrophotometer (ThermoFisher Scientific, Santa Clara, CA). These samples were then
normalized to 25ng/µl placed at -20°C until ready for PCR amplification using the
Amplidex kit.
Buccal swabs
CytoSoft Cytology Brushes (ThermoFisher Scientific, Santa Clara, CA) were sent
to relatives of the couple seeking IVF treatment. Due to the chosen analysis method,
qPCR-based SNP genotyping linkage analysis, relatives must be involved to properly
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track the affected alleles. The recipient of the swab brushed inside the cheeks of their
mouth for 10 seconds each side and mailed the swabs back to the clinic. Once received,
the gDNA isolation began.
Using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) for extraction,
specific alterations were made to ensure proper isolation of the gDNA. 300µl of Cell
Lysis Solution is added to a clean 1.5mL Eppendorf tube. The swab, brush first, is placed
in the same tube and held with sterilized forceps; while the handle of each swab is cut
with sterilized scissors to fit into the tube. 1.5µl of Puregene Proteinase K is added to
each sample and mixed by inverting approximately 25 times. The samples were then
incubated overnight at 55°C.
The following day, the samples are spun down to remove any condensation from
the caps of the 1.5mL tubes. Using sterile forceps, the collection brush was scraped along
the sides of the tube to recover as much liquid as possible. Once enough solution is
recovered, the brush head is discarded. 300µl of 99-100% ethanol is then added to each
sample and vortexed to mix thoroughly. The entire sample was then transferred to an
appropriately labeled DNeasy Mini Spin column placed in a 2mL collection tube. The
samples were centrifuged at 8,000 rotations per minute (RPM) for 1 minute. The
supernatant is discarded and the spin column is placed into a new 2mL collection tube.
500µl of Buffer AW1 is then added to the membrane of each column and centrifuged for
8000RPM for 1 minute again. The flow-through is discarded and the spin column is
placed into a new 2mL collection tube. 500µl of Buffer AW2 is, again, added to the
membrane of each column and centrifuged for 14,000RPM for 1 minute again. The
filtrate is discarded and the spin column is added to a new 2mL collection tube. Without
20

adding any reagents, the samples are placed directly in the centrifuge at full speed
(14,000RPM) for 2 minutes to remove any excess solutions. The remaining filtrates are
discarded and the spin column is placed in a new appropriately labeled 1.5mL tube. 50µl
of AE Buffer is added directly to the membrane of the column and incubated at room
temperature for 1 minute. The samples were then centrifuged at full speed for 1 minute,
with the caps placed counterclockwise to avoid them breaking off. The column is then
removed from the 1.5mL tube and discarded, for the gDNA is now eluted into the AE
buffer. The gDNA in each sample is then quantified using the Nanodrop 8000
spectrophotometer. These samples were then normalized to 25ng/µl placed at -20°C until
ready for PCR amplification using the Amplidex kit.
Chorionic Villi Samples
Chorionic Villi Samples (CVS) are pieces of tissue taken from the villi of the
chorion of a developing fetus, which will eventually form into the placenta. This is a type
of prenatal test used to detect congenital abnormalities; such as the presence of FXS.
gDNA of these samples were isolated using the DNeasy Blood and Tissue Kit
(Qiagen, Valencia, CA). The protocol specifications for gDNA extraction from tissue was
followed. 180µl of Buffer ATL was added to each sample, along with 20µl of proteinase
K. The samples were vortexed for mixing and incubated at 56°C until completely lysed.
This incubation lasted anywhere from 1-2 hours. 200µl of Buffer AL was added to each
sample and mixed thoroughly by vortexing. The samples were incubated at 56°C for 10
minutes. 200µl of 96-100% ethanol was added and mixed by vortexing. The entire
mixture was then transferred into a DNeasy Mini spin column placed in a 2 mL collection
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tube. The samples were spun at 8000 rpm for 1 minute. The flow-through was discarded
and the spin column was added to a new 2mL collection tube. 500µl of Buffer AW1 was
added to each sample and centrifuged for 1 minute at 8000 rpm. The flow-through, again,
is discarded and the spin column is added to a new 2mL collection tube. 500µl of Buffer
AW2 is then added to each sample and centrifuged for 3 minutes at 14,000 rpm. The
flow-through and collection tube were discarded. The spin column was then placed in a
new 1.5mL tube, properly labeled. The DNA was eluted by adding 200µl of Buffer AE to
the membrane of the spin column. The samples were incubated at room temperature for 1
minute and then centrifuged for 1 minute at 8000 rpm. The samples’ DNA concentration
were quantified using the Nanodrop 8000 spectrophotometer because of its ability to
detect larger amounts of DNA. These samples were then normalized to be 25ng/µl placed
at -20°C until ready for PCR amplification using the Amplidex kit.
Amplidex PCR Amplification
All samples were normalized to 25ng/µl, as recommended by Asuragen’s
PCR/CE FMR1 Reagents Protocol Guide (Asuragen, Austin, TX). A positive and
negative control was included. The positive control was provided by Asuragen and is a
Process Control, which contains peaks in all expected allelic ranges. The negative control
consists of 2µl of the diluent, provided by the Amplidex FMR1 Reagent Kit instead of a
DNA sample. The samples were prepared for amplification using the AmplideX FMR1
Reagents Kit. The protocol for CGG RP PCR was followed because of its ability to
produce additional informative data. The PCR master mix consists of 11.45µl of GCRich Amp Buffer, 0.5µl FMR1 F,R FAM Primers, 0.5µl FMR1 CGG Primer, 0.5µl
diluent, 0.05µl GC-Rich Polymerase Mix, 2µl of each pre-amplified DNA sample
22

(including the positive and negative controls) per one reaction. The samples are then
placed in a 2720 thermocycler (Applied Biosystems, Foster City, CA) for the appropriate
cycling protocol as recommended by Asuragen. It began with an initial denaturation step
at 95°C for 5 minutes. Followed by 10 cycles of a continued denaturation at 97°C for 35
seconds, then primer annealing at 62°C for 35 seconds, and ending with extension at
68°C for 4 minutes. There is then another set of 20 cycles, with the same conditions as
the previous 10 cycles; however, 20 seconds is added after every cycle to the last
extension step at 68°C. There is further extension that takes places during a 10 minute
hold at 72°C and then ends with the samples at a 4°C hold until ready for the next step.
Capillary Electrophoresis for Fragment Analysis
The amplified samples are now prepared to be run on the 3730xl DNA Analyzer
(ThermoFisher Scientific, Santa Clara, CA) for capillary electrophoresis (CE). A master
mix is prepared, consisting of 11µl of Hi-Di Formamide and 2µl ROX 1000 Size Ladder
for each expected reaction. 13µl of the prepared master mix is combined with 2µl of PCR
product within a MicroAmp Optical 96 Well Reaction Plate. These samples are then
denatured for 2 minutes at 95°C and stored at 4°C until ready for injection on to the
instrument.
The 3730xl DNA Analyzer is prepared for data acquisition according to
manufacturer’s directions. The run buffer used for this instrument consisted 180mL of
distilled water from a Millipore Ultrapure Water System (Hach, Loveland, CO) and
20mL of 3730 Buffer (10X) with EDTA. The samples are then run on the instrument
using Fragment Sizing Analysis protocols specific to Asuragen’s calibration
requirements. The POP-7 polymer is used, along with a recommendation for 2.5kV at 20
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seconds for each injection on a standard 3730xl with 96 capillaries at 50cm of length. The
run time on the instrument was approximately 1 hour and 45 minutes.
Data Analysis
Data collected from the CE is inputted into GeneMapper5 software. Each sample
shows a display plot exhibiting peaks for each allele that is detected by the instrument.
The display plot is analyzed for each of the samples and size of the peak is determined.
Because the CGG RP PCR protocol was followed, each time a CGG is discovered the
software will automatically call it. To begin analysis, all automatic allele calls are deleted
and the size of gene-specific peaks are then converted into CGG repeat length. One can
determine repeat length by using the following formula:
𝐶𝐺𝐺𝑖 =

𝑃𝑒𝑎𝑘𝑖 − 𝑐0
𝑚0

Where Peaki is the size in base pairs of the gene specific peak, c0 is a size
correction factor, and m0 is the mobility correction factor for each CGG repeat. C0 and
m0 are specific for each standard instrument, ours being 3730xL with 50cm capillaries
for its configuration. Therefore, c0 is equal to 231.9 and m0 is equal to 2.937. From here,
after analyzing the peaks for each sample we can determine the number of repeats and
compare each result against their expected repeat size.
Phase 2:
Cell lines
Human lymphocytes were obtained from Coriell Repository with different CGG
repeat sizes and were cultured in RPMI 1640 with 2X nonessential amino acids, 15%
fetal bovine serum, 2mM L-glutamine at 37°C and 5% CO2. The six different cell lines
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and their respective repeat sizes can be found in table 1.
Table 1: Cell lines used to mimic TE biopsies.
Cell Line

Gender

FMR1 Gene

CGG Repeat Size

GM06889

Female

Normal

30;23

GM06890

Male

Normal

30

GM06891

Male

Premutation

118

GM06894

Female

Premutation

30;78

GM06896 Mosaic Female Mosaic Premutation
GM06897

Male

Full Mutation

23;95-120-140
477

A total of 12 replicates were collected for each cell line and placed into a 0.2mL
PCR tube, making the total sample number 72. Each sample had 6 cells collected in 1μl
of RPMI 1640 using a 100μm stripper tip (Midatlantic Diagnostics, Mount Laurel, NJ,
USA) under a dissecting microscope and placed into a PCR tube. 6 cells were chose to
mimic a TE biopsy to establish the use of the desired method on a limited number of
cells. These samples were used in testing method one, GenomePlex WGA4
Amplification, and method four, targeted pre-amplification. Another set of 72 samples,
containing 6 cells were collected in phosphate buffered saline (PBS), using the same
100μm stripper tip and under the same dissecting microscope as previously described.
These samples were used in method 2, SurePlex DNA amplification, and method 3,
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REPLI-g Single Cell Kit for amplification. Negative controls consisted of 1µl of clean
RPMI 1640 culturing media and 1µl of PBS. 6 replicates for each cell line were used to
test each of the four following amplification methods.
Using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) gDNA was
isolated from each of the 6 cell lines. The protocol was followed for the gDNA extraction
of cells. 2mL of cells were spun down for 5 minutes at 190 rpm; the supernatant was then
removed. The pellet was re-suspended in 200µl of PBS and transferred into a clean
1.5mL tube. 200µl of Buffer AL was added to each sample and mixed thoroughly by
vortexting. The samples were incubated at 56°C for 10 minutes. 200µl of 96-100%
ethanol was added and mixed by vortexing. The entire mixture was then transferred into a
DNeasy Mini spin column placed in a 2 mL collection tube. The samples were spun at
8000 rpm for 1 minute. The flow-through was discarded and the spin column was added
to a new 2mL collection tube. 500µl of Buffer AW1 was added to each sample and
centrifuged for 1 minute at 8000rpm. The flow-through, again, is discarded and the spin
column is added to a new 2mL collection tube. 500µl of Buffer AW2 is then added to
each sample and centrifuged for 3 minutes at 14,000 rpm. The flow-through and
collection tube were discarded. The spin column was then placed in a new 1.5mL tube,
properly labeled. The DNA was eluted by adding 200µl of Buffer AE to the membrane of
the spin column. The samples incubated at room temperature for 1 minute and
centrifuged for 1 minute at 8000 rpm. The samples’ DNA concentration were quantified
using the Nanodrop 8000 spectrophotometer.
Method #1: Single cell lysis and GenomePlex WGA4 Amplification
As mentioned above, these samples were collected in 1µl of RPMI 1640 culturing
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media. The total sample number is 36; 6 replicates from each cell line. The samples are
lysed in alkaline lysis buffer. 7ul molecular biological grade water was added to the PCR
tubes, followed by adding 1μl alkaline lysis buffer [200 mM KOH and 50 mM DTT].
The samples are then incubated at 65°C for 10 min. 1ul neutralization buffer [0.9 M Tris–
HCl, pH 8.3, 0.3 M KCl and 0.2 M HCl] is added to the sample to neutralize the lysis
buffer. The lysates were snap frozen with liquid nitrogen and stored at -20°C until ready
for amplification using the Amplidex kit.
DNA of the lysed cells is amplified by WGA using the GenomePlex WGA4 kit as
recommended by the supplier (Sigma Aldrich Inc). 2µl of 1X library preparation buffer
was added to the side of the tube, above the 10µl sample. The sample was spun down to
consolidate the solutions, vortexed to ensure adequate mixing of the solutions, and then
spun again. 1µl of library stabilization solution is then added to the tube. The samples is
the spun, vortexed and spun again. The samples were incubated at 95°C for 2 minutes in
a 2720 thermocycler (Applied Biosystems, Foster City, CA). The samples were briefly
spun down to consolidate the solutions and moved to ice for cooling. 1µl of library
preparation enzyme is added to the samples and flicked to ensure mixing. The samples
were spun down before incubating in the 2720 thermocycler for the following conditions:
16°C for 20 minutes, followed by 24°C for 20 minutes, then 37°C for another 20 minutes,
finishing with 75°C for 5 minutes and ending at 4°C until ready for the next step. Next,
the amplification master mix was made consisting of 7.5µl of the 10X amplification
master mix, 48.5µl of nuclease-free water, and 5µl of WGA DNA polymerase for each
reaction. The master mix was vortexed and spun to consolidate the solution. Each sample
received 61µl of this master mix and was vortexed and spun to guarantee appropriate
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mixing for each sample. The samples incubated at 95°C for 3 minutes for the initial
denaturation, 25 cycles of another denaturation at 94°C for 30 seconds, annealing and
extension at 65°C for 5 min and ending with a hold at 4°C. The WGA DNA is purified
using GenElute PCR cleanup columns (Sigma Aldrich Inc, St. Louis, MO). Before
conducting the purification the tubes needed preparation. 3 tube racks were obtained and
one 1.5mL tube for each sample, closed and empty, were placed in the first rack. Opened
1.5mL tubes were placed in the second rack and 375µl of binding solution was aliquoted
into each. 2mL tubes from the clean-up kit were placed in the third rack and a spin
column was placed into each. 500µl of column prep solution was added to each column
and spun at 12 RCF for 1 minute using the 5424 centrifuge (Eppendorf, Mount Laurel,
NJ, USA). All tubes had appropriate labels for their corresponding samples.
The amplified samples were spun before beginning the clean-up protocol. Each
sample was added to the 1.5mL binding solution tubes and vortexed and spun for mixing.
The sample, now combined with the binding solution, was added to the spin column and
spun at 12 RCF for 1 minute. The supernatant was discarded. 500µl of diluted wash
solution was added to the spin columns and spun at 16.1 RCF for 1 minute. The
supernatant was discarded. The samples were spun again at max speed for 2 minutes to
further dry the column. The spin column was transferred from the 2mL tube to the clean
empty 1.5mL tubes. 50µl of elution solution was added to the spin column and incubated
at room temperature for 1 minute. The samples were spun at maximum speed for 1
minute and the spin columns were discarded. The samples were quantified using a
Nanodrop 8000 spectrophotometer. The only alteration being that the blank used for this
method was the elution solution provided in the clean-up protocol. These samples were
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then normalized to be 40ng/µl placed at -20°C until ready for Amplidex PCR
amplification.
Method #2: SurePlex DNA Amplification System
The SurePlex DNA Amplification System requires cell collection to begin with
1.5µl of PBS into PCR tubes, with the addition of the 6 cells from each cell line in 1µl of
PBS. The lysis protocol is then followed as recommended by Illumina. 2.5µl of collection
buffer was added to each sample and centrifuged at 200g for 3 minutes, using the same
centrifuge as mentioned in the first method. 2.5µl of cell extraction buffer was added to
the samples. They were spun, vortexed and spun again to ensure sufficient mixing. The
samples were placed on ice while the extraction cocktail master mix was prepared. For
one reaction, the master mix contained 4.8µl of extraction enzyme dilution buffer and
0.2µl of cell extraction enzyme. 5µl of the master mix was added to each sample and
spun down to consolidate the solutions. They were vortexed to mix the solutions
thoroughly and spun again. The samples incubated at 75°C for 10minutes, then 95°C for
4 minutes and then placed at 25°C until ready for pre-amplification.
DNA of the lysed cells is amplified by WGA using the SurePlex DNA
Amplification Kit as recommended by Illumina (San Diego, CA). The pre-amplification
master mix for one reaction contained 4.8µl of SurePlex pre-amp buffer and 0.2µl of
SurePlex pre-amp enzyme. 5 µl of the master mix was added to each sample and
vortexed and spun to ensure consolidation. The samples incubated at 95°C for 2 minutes
to begin enzyme activation then endured 12 cycles at 95°C for 15 seconds, 15°C for 50
seconds, 25°C for 40 seconds, 35°C for 30 seconds, 65°C for 40 seconds, followed by
75°C for 40 seconds. Finishing with a 4°C hold until ready for amplification.
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For one reaction, the amplification master mix contained 25µl of SurePlex
amplification buffer, 0.8µl of SurePlex amplification enzyme, and 34.2µl of nuclease-free
water. The master mix was vortexed and spun down for consolidation. 60µl of the master
mix was added to each sample and vortexed. The samples were spun before incubation at
95°C for 2 minutes to start enzyme activation, then 14 cycles of 95°C for 15 seconds,
65°C for 1 minute, and 75°c for 1 minute. Ending with a 4°C hold until ready for
quantification.
The samples are then quantified using the Qubit 2.0 Fluorometer (ThermoFischer,
Santa Clara, CA) as recommended by Illumina. To begin, the Qubit dsDNA HS working
solution was prepared for 48 samples consisting of 11.945mL of dsDNA HS buffer and
55µl of dsDNA HS reagent. We only had 36 samples, so the left over master mix was
stored at 4°C. 190µl of the working solution was added to the Qubit assay tubes, one for
each sample. A 1:10 dilution was conducted for each sample. 10µl of each dsDNA HS
standard and 10µl of each sample were added to the Qubit assay tubes, containing the
190µl of the working solution. The samples were spun, vortexed, and spun again. They
incubated for 2 minutes at room temperature, while calibration of the instrument occurred
using the dsDNA HS standards. Each sample was then quantified and the concentration
was recorded and converted to ng/µl. A GeneVac from Eppendorf (Eppendorf, Mount
Laurel, NJ, USA) was used to evaporate excess water from samples with concentrations
lower than 40ng/µl. After being dried, the samples were normalized to 40ng/µl and stored
at -20°c until ready for the Amplidex PCR amplification.
Method #3: REPLI-g Single Cell Kit
The samples used for this method were collected using PBS. The PCR tubes were
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prepped with 3µl of PBS before collection occurred. After collection, 3µl of Buff D2 is
added to the 4µl of cell material (supplied with PBS) and incubated at 65°C for 10min.
3µl of the stop solution is added to halt the reaction and flicked to ensure thorough
mixing. DNA of the lysed cells is amplified by WGA, utilizing a multiple displacement
amplification (MDA) methodology, using the REPLI-g Single Cell Kit as recommended
by Qiagen. For one reaction, the master mix consisted of 9µl of nuclease-free water, 29µl
of REPLI-g reaction buffer, and 2µl of REPLI-g DNA polymerase. The master mix was
vortexed and spun to ensure adequate mixing. 40µl of master mix was added to each 10µl
sample of denatured DNA. The samples incubated at 30°C for 8 hours. Followed by a 3
minute incubation at 65°C to inactive the REPLI-g DNA polymerase.
Before quantification, the samples needed to undergo a purification procedure.
The procedure chosen was a beads purification protocol using Ampure XP Beads. Before
beginning, fresh 70% ethanol was prepared and the Ampure Beads were removed from
the refrigerator to reach room temperature. The full 50µl volume of each sample was
transferred to a 96 well plate. The amount of beads needed for each sample is 1.8 times
the volume of the sample; i.e. 50µl x 1.8 = 90µl of Ampure beads. The plate, containing
the samples and beads, was sealed, vortexed and spun to ensure thorough mixing. The
samples incubated at room temperature for 5 minutes and were then put onto a magnetic
rack. Once the magnetic beads formed a pellet and the liquid cleared, the supernatant was
removed. After use with the REPLI-g amplification kit, the samples were very sticky and
required additional scraping of the excess beads off of the sides of the wells. 200µl of the
freshly prepared 70% ethanol is added to each well containing a sample. The plate was
moved around the magnetic rack a couple times to ensure adequate washing. The
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supernatant was removed and another 200µl of 70% ethanol was added. This last step
was repeated 4 times, resulting in 4 washes. Once the last supernatant was removed, the
plate was sealed and the residual ethanol was spun down. All ethanol was removed from
each of the samples. While removing the remaining ethanol that settled after being spun,
the pellets were dried for 3 minutes at room temperature. 50µl of nuclease-free water was
added to each well, while off the magnet, and mixed properly to re-dissolve the pellets.
The plate was sealed and incubated at room temperature for 2 minutes. It then was
vortexed and spun down. Lastly, the plate was placed back onto the magnetic where the
pellet reformed. The supernatant was removed and placed into a new, properly labeled,
PCR tube.
These samples were then quantified using the Agilent 2200 TapeStation System
(Agilent Technologies, Santa Carla, CA). The specific protocol used was the one for
gDNA to allow visualize of larger bands. 10µl of Genomic DNA Sample Buffer was
mixed with 1µl of the Genomic DNA Ladder within the first well of the plate being used.
Following down the same column, 10µl of Genomic DNA Sample Buffer was mixed
with 1µl of each sample. The plate was vortexed and spun down to consolidate all
reagents. It was placed into the 2200 TapeStation system. Because of the TapeStation’s
ability to only detect concentrations between 0 and 100ngµl, it was unsuitable for use
with our samples. The next option was the Nanodrop 8000 spectrophotometer because of
its ability to detect larger concentrations. This method had better specificity for our
samples because of their high DNA concentrations (~600ngµl). Each sample was
normalized to 40ng/µl using the concentrations from the Nanodrop and stored at -20°c
until ready for the Amplidex PCR amplification.
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Method #4: Single Cell Lysis and Targeted by Pre-Amplification of Specific FMR1 Gene
All replicates of 6 cell aliquots were lysed according to the same lysis protocol as
described in method 1.
Initially, primers had to be created to specifically target the FMR1 gene and was
done using Integrated DNA Technologies (IDT, Corlaville, IA). Additionally, Jean
Wilson’s publication in the Journal of Molecular Diagnostics34 was used to create a
forward and reverse FMR1 primer to target the entire FMR1 gene. The forward primer
read as follows: 5’ – 6FAM-GGAACAGCGTTGATCACGTGACGTGGTTTC-3’ and
the reverse primer read as: 5’-GGGGCCTGCCCTAGAGCCAAGTACCTTGT-3’. For
one reaction the master mix for the pre-amplification consisted of 25µl of Taqman
PreAmp master mix (ThermoFisher Scientific, Santa Clara, CA), 2.5µl of the 10µM
FMR1 forward primer, 2.5µl of the 10µM FMR1 reverse primer and 10µl of nucleasefree water were all combined to create the master mix used in this amplification method.
The master mix was vortexed and spun to guarantee suitable mixing of the reagents.
Then, 40µl of the master mix was added to each sample. The samples were then spun,
vortexed and spun down again. The thermocycling conditions for the 2720 thermocycler
(Applied Biosystems, Foster City, CA) began with 95°C for a 10 minute enzyme
activation hold, then 18 cycles of 95°C for 15 seconds, 60°C for 4 minutes, and ending at
4°C until ready for the next steps. This part of the protocol was altered from 18 cycles, to
24 cycles, then to 30 cycles, then to 36 cycles and finally ended with 42 cycles of preamplification.
No quantification is necessary for these samples since the targeted amplicon is too
small to produce a needed concentration of 40ng/µl. The samples were stored at -20°C
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until ready for Amplidex PCR Amplification.
To ensure the IDT FMR1 primers were outside the FMR1 region, next-generation
sequencing (NGS) was conducted to confirm its position. A control aneuploid male cell
line 1359 with a normal FMR1 gene was used sequencing, along with a negative control
of water. The sample underwent the pre-amplification steps as previously described and
were stored at -20°C until the Amplidex Gene-Specific protocol was conducted.
FX Gene-Specific PCR Amplification for Sequencing in Method 4
The two samples, control sample 1359 and a negative control were prepared for
Gene-Specific PCR using the same Amplidex FMR1 Reagent Kit as recommended by
Asuragen. The PCR master mix consisted of 11.45µl of the GC-Rich amplification
buffer, 0.5µl of the FMR1 F,R FAM primer, 1µl of the diluent, and 0.05µl of the GCRich Polymerase Mix per one reaction. The master mix was thoroughly mixed by
vortexing and 13µl was dispensed into each new PCR tube. 2µl of each sample was
added to its appropriately labeled tube. The samples were then vortexed and spun down
to consolidate the reagents. They were then put into a 2720 thermocycler and were
subjected to the following conditions: 98°C for a 5 minute hold, then 25 cycles at 97°C
for 35 seconds, 62°C for 35 seconds, 72°C for 4 minutes, and finished off with another
extension at 72°C for 10 minutes. A simple way to describe the difference between the
Gene-Specific PCR protocol and the CGG RP PCR protocol is the use of the third primer,
FMR1 CGG primer. It makes up part of the master mix in the CGG RP PCR but is not
included in the Gene-Specific protocol. There is also only one set of PCR cycles in the
Gene-specific protocol compared to the CGG RP PCR. Following this PCR, the Agilent
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Tape Station was used to determine the size of the amplicon.
Next-Generation Sequencing using PGM
Due to the size of our amplicon being less than 400bp, the protocol was started at
the end-repair section. 79µl of nuclease-free water was added to each sample because
there was 100ng of input DNA. Additionally, there was 20µl of 5X end repair buffer and
1µl of end repair enzyme added to each sample. The samples were incubated for 20
minutes at room temperature. To purify the samples, 180µl of the AmPure XP Reagent
beads was added to each sample. The samples were vortexed to mix thoroughly and
placed on a magnet to for 3 minutes, or until the solution cleared. The supernatant was
removed and 300µl of freshly made 70% ethanol was added to each. The samples were
moved around the magnet to thoroughly wash the beads. The supernatant again, was
removed and the washing step was repeated one additional time. The samples were spun
down to remove all residual ethanol and left at room temperature to dry for about 5
minutes. The pellet of beads was removed from the magnet and re-dissolved in 25µl of
low TE buffer and mixed by vortexing. The samples were spun down and placed back on
the magnet until the solution cleared. The supernatant was removed and placed in a new
appropriately labeled tube.
Ligate and nick-repair was the next step followed. Because barcodes were added
to the samples, the reaction was setup for barcoded libraries. Added to the 25µl of eluted
DNA was 10µl of 10X ligase buffer, 2µl of Ion P1 adapter, 2µl of Ion Xpress Bardcode
X3, 2µl of dNTP Mix, 49µl of nuclease-free water, 2µl of DNA ligase, and 8µl of nickrepair polymerase. Each sample was vortexed and then spun down before placed in the
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2720 thermocycler. The conditions followed were 25°C for 15 minutes, 72°C for 5
minutes, and held at 4°C until ready for the next purification. The purification began with
adding 150µl of the AmPure XP Reagent beads and then the steps were followed
identical to the purification that occurred after the end-repair protocol.
The amplification began with 25µl of DNA, 100µl of the Platinum PCR
SuperMix High Fidelity and 5µl of library amplification primer mix was added to each
sample. The tubes were placed in a 2720 thermocycler under the following conditions:
95°C for 5 minutes to denature the DNA, followed by 8 cycles of 95°C for 15 seconds for
additional denaturing, 58°C for 15 seconds for annealing to occur, 72°C for 1 minute of
extension, ending with a 4°C hold until ready for the final purification. The amount of
beads added to each sample was 195µl. The rest of the protocol was followed identically
to the purification that occurred after end-repair. The elution step involved the addition of
20µl of low TE buffer, instead of the previous 25µl.
The Personal Genome Machine (PGM) (ThermoFisher, Santa Clara, CA) was
setup as recommended by Thermofisher Scientific.
Amplidex PCR Amplification for All Four Methods
All pre-amplified samples are then prepared for amplification (protocol provided
by Asuragen) using the AmplideX FMR1 Reagents Kit, as described in phase 1. A
positive and negative control were included, as described previously in phase 1. The
samples are then placed in a 2720 thermocycler for the appropriate cycling protocol as
recommended by Asuragen, also described previously in phase 1.
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Capillary Electrophoresis for Fragment Analysis
The amplified samples are now prepared to be run on the 3730xl DNA Analyzer
for CE, aforementioned in phase 1. The 3730xl DNA Analyzer is prepared for data
acquisition according to manufacturer’s directions (Sanger Sequencer Genetic Analyzer,
Applied Biosystems). The samples were run on the instrument using Fragment Sizing
Analysis protocols specific to Asuragen’s calibration requirements, also mentioned
previously in phase 1.
Data Analysis
The data to be analyzed is exported from 3730xl Genetic Analyzer and inputted
into GeneMapper5 software, as described previously in phase 1. All automatic allele calls
are deleted and must be manually chosen based on the criteria provided by the Asuragen
manual. After analyzing the peaks for each sample, we can determine the number of
repeats and compare each of our methods.
Continuation of Confirmation using REPLI-g Single Cell Kit for Amplification
To progress onto phase 3, the REPLI-g Single Cell Kit for amplification was
chosen. An additional 48 samples, consisting of either cells from cell lines or gDNA,
were collected and de-identified to provide extra confirmation that the amplification and
following methodology works accurately. These samples underwent the lysis method as
recommended by Qiagen using the REPLI-g Single Cell kit, along with the amplification
procedure. The samples were purified using the beads purification protocol as previously
described. The samples were normalized to 40ng/µl and followed by PCR using the
Amplidex FMR1 reagent kit. Lastly, CE on the 3730xl DNA analyzer was conducted and
the data was analyzed using the GeneMapper5 software.
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Phase 3:
To begin, 3 more replicates from each cell line were used to test whether or not
the single cell lysis protocol will work successfully with the REPLI-g Amplification
system. The cells were lysed using the single cell lysis method described in phase 2,
method 1. Then they underwent the REPLI-g amplification, followed by the Amplidex
PCR and the CE. Once validated, the amplification kit could be used on arrested embryos
that were already stored as lysates.
Use of Discarded Arrested Embryos
12 arrested embryos from patients seeking IVF treatment for FXS were obtained
from long-term cyro storage in a liquid nitrogen dewer. The quality of each embryo at the
point it arrested was either 5 cells, 8 cells, or a morula. No PGD testing had been
conducted to observe chromosome copy number because each embryo did not reach the
required blastocyst stage. Therefore, the arrested embryos were lysed as described in
phase 2, method 1 before being provided for this study.
REPLI-g Amplification
The REPLI-g amplification kit was used, aforementioned in phase 2, method 3.
The samples underwent a beads purification, previously described in phase 2 under
method 3. The samples were then quantified using the Nanodrop 8000
spectrophotometer. The samples were treated similarly to the cell lines and normalized at
40ng/µl.
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Amplidex PCR Amplification, CE, and Data Analysis
Amplidex PCR amplification was conducted as previously mentioned in phase 1.
Followed by the CE using the 3730xl DNA analyzer. The data analysis was conducted in
the same fashion as in the previous phases using GeneMapper5 software.
Genotyping
After conducted the previous experiments, genotyping was done to determine the
gender of each embryo. The previously normalized samples were diluted from 40ngµl to
5ng/µl in 50µl of total volume. Simultaneously, a master mix is made consisting of 2.5µl
of Taqman Gene Expression Master Mix, 0.125µl of the AmelXY assay, and 0.375µl of
water per 1 reaction. A separate master mix was made for another version of a gender
assay called ANACKX assay. The same volume was added to another master mix created
with the same parameters. 3µl of the master mix is added to each appropriate well on a
384 well plate. Then, 2µl of each DNA sample is then added to the appropriate wells.
Each DNA sample was run with the two different assays. The plate is vortexed and spun
to ensure adequate mixing. An SDS file is then made using SDS 2.4 software to create
the plate layout for the 7900 Fast Real Time PCR System (ThermoFisher, Scientific,
Santa Clara, CA). The plate is initially ran on a GeneAmp 9700 PCR system (Applied
Biosystems, Foster City, CA) under the following conditions: 50°C for 2 minutes, then
95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1
minutes, ending with a final hold at 4°C. The plate was then run on the 7900 Fast Real
Time PCR System (ThermoFisher Scientific, Santa Clara, CA) to conduct a post read for
analysis.
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Phase 4:
Collection of Discarded Whole Aneuploid Embryos
5 discarded whole aneuploid embryos were used throughout this phase and are
listed in table 2. They were biopsied using Olympus TH4-100 Biopsy and microinjection
microscope working system.
Table 2: Discarded Whole Aneuploid Embryos Used
Embryo
#

Ploidy
Status

1

Aneuploid

2
5

Aneuploid
Aneuploid

PCR 24
Results
47,XX,1,+3,+10
47,XX,+10
47,XY,+2

4

Aneuploid

47,XXX

3

Aneuploid

45,XX,-9

FX Affected?

Gender

yes

F

no
yes
Inconclusive
(XXX)
no

F
M
F
F

Single Cell Lysis
Lysis was conducted on all biopsies from each embryo, previously described at
the beginning of amplification method 1. After following the necessary steps, the lysates
were stored at -20°C until ready for amplification.
Amplification using REPLI-g Single Cell Kit
DNA of the lysed cells were amplified by whole genome amplification (WGA)
using the REPLI-g Single Cell Kit as recommended by Qiagen, aforementioned in
amplification method 3.
Before quantification, the samples underwent a purification procedure, as
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mentioned above in amplification method 3. The procedure chosen was a beads
purification protocol using Ampure XP Beads.
The samples were quantified using the Nanodrop 8000 spectrophotometer. Each
sample was normalized to 40ng/µl using the concentrations from the Nanodrop and
stored at -20°c until ready for the Amplidex PCR amplification.
Amplidex PCR Amplification
All pre-amplified samples are then prepared for amplification (protocol provided
by Asuragen) using the AmplideX FMR1 Reagents Kit, as described in phase1 and again
referenced in phase 2 under Amplidex PCR amplification for all four methods.
Capillary Electrophoresis POP-7
The amplified samples are now prepared to be run on the 3730xl DNA Analyzer
for CE, previously mentioned in phase 1. The 3730xl DNA Analyzer is prepared for data
acquisition according to the manufacturer’s directions (Sanger Sequencer Genetic
Analyzer, Applied Biosystems). The samples are then run on the instrument using
Fragment Sizing Analysis protocols specific to Asuragen’s calibration requirements, also
mentioned previously in phase 1.
Data Analysis
The data to be analyzed is exported from 3730xl Genetic Analyzer and inputted
into GeneMapper5 software, as described previously in phase 1. All automatic allele calls
are deleted and must be manually chosen based on the criteria provided by the Asuragen
manual. The data from this final phase will serve as additional validation of the
developed method and confirmation that the method works on clinical samples.
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Next-Generation Sequencing using the Ion Torrent Proton
Because the aneuploid whole embryos were testing using CCS a few years ago,
the CCS platforms have changed. Previously, PCR-24, a qPCR based CCS method for
aneuploidy screening was used for all biopsies. Currently NexCCS, a NGS based CCS
method is now used as a more sensitive method for CCS. NexCCS was conducted on
biopsies from the aneuploid whole embryos to compare the CCS methods. A 10µl lysate
from each aneuploid whole embryo was used. They first underwent pre-amplification. A
master mix was created using 25µl of Taqman PreAmp Master Mix, 2.5µl of a universal
reverse primer, and 10µl of water for every 1 reaction. The master mix was mixed
thoroughly before added to each lysate. Then, 2.5µl of a unique fusion primer, or
barcode, was added to each sample as an identifier. The samples were mixed thoroughly
and spun down to consolidate the solutions. The samples were then placed in a 2720
thermocycler under the following conditions: 95°C for a 10 minute hold, then 24 cycles
of 95°C for 15 seconds, 60°C for 4 minutes, and ending with a 4°C hold until ready for
the next step.
The samples were then quantified using the Agilent TapeStation as described
previously to ensure the amplicons are present. All the samples are then normalized to
15ng and pooled together. They then underwent a beads purification protocol, as
previously described. The prepared library is then quantified on the Agilent TapeStation
again. The library is then normalized to 50pmol and placed at 4°C until ready to be
loaded on the Ion Chef Instrument (ThermoFisher Scientific, Santa Clara, CA) according
the manufactures recommended instructions. The ion chef creates the chip that will then
be loaded onto the Ion Torrent Proton for Next-Generation Sequencing (ThermoFisher
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Scientific, Santa Clara, CA). Once the chip is loaded, it is placed on the Proton following
the manufactures recommendations. From there, the data is analyzed using an algorithm
created by a bioinformatics team and the chromosome copy number plots are created
needing further analysis.
RESULTS
Phase 1:
PCR and CE was conducted to determine the CGG repeat size for all the known
samples that were used in this phase. gDNA was previously isolated from blood or buccal
swabs from patients seeking IVF treatment for FXS, or chorionic villi samples from the
fetus of a similar patients. After amplifying the gDNA with the Amplidex PCR and
following with CE, each sample’s CGG repeat sizes were compared to that of two
reference labs. As seen in table 3, the CGG repeat sizes for each sample listed under the
column ‘In House’ was within 0-3 CGG repeats33, as expected, compared to the results
provided by the two reference labs. With all 17 samples showing an exact match to at
least one of the reference labs’ results, this method has shown to be very reliable for
testing for CGG repeat sizes on gDNA.
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Table 3: Results of gDNA run using Asuragen's Amplidex Kit

Sample ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

CGG Repeat Numbers
Reference Lab #1
Reference Lab #2
31
125
30
126
31
30
31
75
30
74
29
92
28/29
93/94
29
56
29
56
24
22/23
30
>200
29/30
>200
>200
>200
30
74
29
74
10
89
10
87
29
75
30
75
31
85
31
86
24
79
23
79/80
>200
>200
30
30
29
30
55
54
90
93

In House
30
126
30
30
74
29
93
29
56
23
30
319
287
29
74
11
87
30
75
31
86
23
79
316
29
30
54
93

Figure 1 is a display plot from the analysis program GeneMapper5 software and is
an example of an electropherogram after use of the CGG RP PCR method. Each time a
CGG repeat is detected, it is marked on this display plot with a blue line. To clarify, the
x-axis is the number of base pairs and the y-axis is the signal intensity. The space
between the first 10 CGG peaks detected and the next 10 is representative of the AGG
interruption, denoted by the black arrow. These interruptions, aforementioned in the
introduction, help maintain stability of the gene. The two, more intense, peaks are labeled
as the gene-specific peaks. The sizes of these peaks can be converted to CGG repeat
length using the formula discussed in the methods of phase 1. Because the FMR1 gene is
on the X chromosome, samples from a female will display two intensified peaks, such as
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in figure 1, and males will exhibit only 1 intensified peak. Specifically for figure 1, the
sample is a female exhibiting a peak within the normal range and a peak within the
premutation range for CGG repeat size. Therefore, it can be determined that this female
patient has one normal X chromosome with 29 repeats and her other X chromosome
exhibits a FMR1 gene within the premutation range with 93 repeats. She is also fortunate
to have two AGG interruptions that were not lost in transmission, since she does exhibit a
premutation FMR1 allele.

Genespecific
peaks

CGG
Peaks

Figure 1: Display plot for gDNA sample number 4.

Phase 2:
6 replicates from each cell line, containing 6 cells to mimic a trophectoderm
biopsy, were used to test the four previously mentioned amplification methods. The same
Amplidex PCR, CE and data analysis were conducted for all four methods. The only
difference is method 4 had additional tests done for confirmation purposes.
Amplification Method #1 Single cell lysis and GenomePlex WGA4 Amplification &
Method 2: SurePlex DNA Amplification System
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After conducting PCR and CE on the whole genome amplified DNA described in
methods 1 and 2, there were no CGG or gene-specific peaks detected in the display plots.
As seen in figure 2, there were no gene-specific peaks detected at all for the GenomePlex
WGA4 Amplification method. There were 6 replicates run for each of the 6 cell lines,
totaling 36 samples for this method and all samples exhibited this same result. Figure 3
displays results for the SurePlex DNA Amplification system. There were no peaks
detected using this WGA method as well.

Figure 2: Display plot for sample 06890_1 used with GenomePlex WGA
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Figure 3: Display plot for sample 06894_V used with SurePlex amplification.

Method #3: REPLI-g Single Cell Kit
Although the REPLI-g Single Cell Kit for amplification is also a WGA method, it
is specifically a multiple displacement amplification (MDA). It was expected for this kit
to work more efficiently for longer products compared to the two previous WGA
methods that were not MDA versions. As seen in figure 4, there are CGG peaks present
at the beginning of the display plot, along with 2 AGG interruptions present. The genespecific peak shown on the display plot has a high signal intensity, which gave great
confidence that this method worked accurately.
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Figure 4: Display plot for 06890_2 used with the REPLI-g amplification.

Method #4: Single Cell Lysis and Targeted by Pre-Amplification of Specific FMR1 Gene
During the last and final amplification method, a lot of trial and error occurred. To
ensure the FMR1 primer that was created would anneal outside our desired region, NGS
using the PGM was conducted. The sequencing results can be observed in figures 5A and
5B. Figure 5A shows the presence of the forward FMR1 primer that was created; while
figure 5B shows the presence of the reverse FMR1 primer. As discussed in the materials
and method section, the number of cycles conducted for the pre-amplification step was
altered many times. The number of cycles began at 18 and was increased by 6 cycles.
After every 6 cycles, the Amplidex PCR and CE was conducted to observe if any peaks
would be detected in the display plot. No peaks were observed until the samples
underwent a total of 42 cycles and those results can be seen in figure 6. The signal
intensity of the peak is very low, but still remains above the cut-off threshold for the
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3730xl DNA Analyzer. In order to not waste lysates from the FX cell lines, a lysate from
a control aneuploid cell line 1359 that was available was used until a peak was detected.

Forward FMR1
Primer Sequence

Figure 5A: NGS results confirming the
presence of the forward FMR1 primer
created.

Reverse FMR1 Primer
Sequence

Figure 5B: NGS results confirming
the presence of the reverse FMR1 primer
created.

Figure 6: Display plot of only peak displayed with targeted amplification.

When 42 cycles of pre-amplification were conducted on samples from the cell
lines the results look abnormal. There are too many peaks that reach above the gene49

specific signal intensity threshold. All 6 replicates from each of the 6 cell lines exhibited
similar results. From these results, the decision was made to move forward onto phase 3
using the REPLI-g Single Cell Kit for amplification.

Figure 7: Display plot of samples with IDT FMR1 primer and 42 cycles of preamp.

Continuation of Confirmation using REPLI-g Single Cell Kit for Amplification
To evaluate the method further, the cell line samples were blinded and then run
through the same steps as previously described. The samples were de-identified and
given new ID’s before the amplification using the REPLI-g kit began. The same process
was followed and results are shown in figure 8. Two peaks within the normal range, with
satisfactory signal intensity, were observed in the electropherogram. Therefore, blinding
the samples allows for further evaluation of the methodology when the expected results
are unknown.
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Figure 8: Display plot for Sample ID #26.
Phase 3:
Progressing onto phase 3, the REPLI-g Single Cell Kit for amplification was
chosen for continued use throughout this project. First, the Single Cell Lysis method
needed to be tested to observe if it works concurrently with the REPLI-g Single Cell Kit.
Therefore, 2 more replicates from each cell line were used to test whether or not the
single cell lysis protocol will work successfully with the REPLI-g Amplification system
instead of the lysis method recommended by Qiagen for the REPLI-g kit. It was observed
that the lysates worked when they underwent the REPLI-g amplification, the Amplidex
PCR and the CE. This step is necessary because the arrested embryos, used later in phase
3, are stored as lysates.

Use of Arrested Embryos with Methodology
The next step was to involve the use of arrested embryos from patients seeking
IVF for FXS. These embryos were treated identically to the cell lines. The samples were
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previously lysed, therefore the first step involved undergoing the REPLI-g amplification.
The samples then underwent the Amplidex PCR and ended with CE on the 3730xl DNA
Analyzer. 10 out of 12 of the samples produced reliable results. Figure 9 exhibits the
display plot for one of the arrested embryo samples that displayed good signal intensity.

Figure 9: Display plot for arrested embryo 2 replicate C.
Two samples did not produce any signal to be detected by the CE. A question
arose if those two samples had any commonalities between them. During this time the
samples underwent genotyping to determine the gender of each; while simultaneously
comparing the results to the embryo quality. Two different gender assays were used to
confirm the proper call for each arrested embryo. Figure 10A presents the gender assay
results for the assay AMELXY. If the samples exhibited the VIC probe with a blue dot,
then the samples were female. If the samples exhibited the FAM probe with a red dot,
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then the samples were determined as male. There are some samples that showed up as
heterozygous for both and labeled with a green dot. Those were determined to obtain
over amplified male gDNA. In figure 10B, the results for the ANAACKX gender assay
differ from AMELXY assay. For ANAACKX, the female samples are labeled red for the
FAM probe and the male samples are labeled green for being heterozygous for both VIC
and FAM. There were some male samples again that over amplified again and those are
labeled blue for the VIC probe. Table 4 displays the gender results for each arrested
embryo used compared to the embryo quality. The embryo quality is defined as the cell
stage of an embryo when it arrested.
Table 4: Demographics of arrested embryos.
Sample
ID
50318a14
55138a1
55138a23
55970a7
55970a10
55970a12
42619a3
42619a8
42619a9
49053a6
49053a7
49053a8

Embryo
Quality
5 cell
Morula
6 cell
8 cell
8 cell
Morula
8 cell
Morula
8 cell
Morula
8 cell
5 cell

Gender
Female
Male
Female
Female
Male
Female
Female
Female
Male
Female
Female
Male

Repeat
Size
32;38
30
32;39
31;60
30
30;31
30;30
x
x
28;29
28;28
29
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Figure 10A: Genotyping results for gender Figure 10B: Genotyping results for gender
assay AMELXY.
assay ANAACKX.

Phase 4:
Use of TE biopsies with Methodology
Once retrieved from long-term cryo-storage, the whole embryos were biopsied
into small clinically approved sizes. It was unclear how many cells were in each biopsy,
but the operator attempted to make each biopsy around the same size. The use of biopsies
from whole embryos marks the final stage of the project. These samples are identical to
the samples that would be run using this methodology if it were to become clinically
implemented. The whole embryos that were biopsies can be found in table 5.
Table 5: The discarded aneuploid whole embryos used for the final phase.
Embryo
#

Ploidy
Status

1

Aneuploid

2
5

Aneuploid
Aneuploid

PCR 24
Results
47,XX,1,+3,+10
47,XX,+10
47,XY,+2

4

Aneuploid

47,XXX

3

Aneuploid

45,XX,-9

FX Affected?

Gender

yes

F

no
yes
Inconclusive
(XXX)
no

F
M
F
F

The CCS method of these embryos at the time of their fertilization was PCR 24,
which is a qPCR based method for aneuploidy screening. Therefore, simultaneously the
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DNA from the biopsies of these embryos was also run on NGS to compare the CCS
results. Below in figure 12, are the chromosome copy number plots for both qPCR and
NGS. The qPCR method displays the chromosome number along the x-axis and the
chromosome copy number along the y-axis. Each number, meaning 0, 1, 2, or 3, has a
threshold that needs to be reached in order for the algorithm to detect it. For the example
in figure 11A, this karyotype was determined as 45, XX, -9. Comparatively, the NGS
algorithms are a bit different. They display each amplicon and its copy number for each
chromosome. Along the x-axis is the chromosome number and along the y-axis is the
copy number. In figure 11B, there is an extra plot for NGS analysis that exhibits the
alternative allele fraction for each amplicon as well. Allele fraction can be defined as the
percentage of a sample represented by an allele.

Figure 11A: qPCR chromosome copy
number plot.

Figure 11B: NGS chromosome copy
number plot.

After running the REPLI-g amplification, the Amplidex PCR, and the CE, the
results for the biopsies were as expected. In figure 12, the display plot presents a peak
within the normal range and a peak within the premutation range for this female embryo.
This plot exhibits the accuracy of our method because the peaks show quality signal
intensity.
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Figure 12: Display plot for embryo 1
Overall, table 6 briefly displays a comparison of demographics of the aneuploid
whole embryos used. These demographics include NexCCS (NGS based CCS), which
proved to be a more sensitive method for CCS, and the inheritance patterns of their
alleles. Data within the highlighted light blue section of the table was determined
throughout the last phase of this project.

56

Table 6: Overall comparison of the aneuploid whole embryos used
Embryo
Gender
#
1-A

F

1-B

F

2-A
2-B
3-A
3-B

F
F
F
F

PCR 24
Results
47,XX,1,+3,+10
47,XX,1,+3,+10
47,XX,+10
47,XX,+10
45,XX,-9
45,XX,-9

NexCCS
Results
46,XX,1,+10
46,XX,1,+10
46,XX
46,XX
45,XX,-9
45,XX,-9

4-A

F

47,XXX

46,XX

4-B

F

47,XXX

46,XX

5-A
5-B

M
M

47,XY,+2
47,XY,+2

46,XY
46,XY

FX
Affected?

CGG
Repeats

yes

29;74

yes

29;74

no
no
no
no
Inconclusive
(XXX)
Inconclusive
(XXX)
yes
yes

29;29
29;29
32;36
32;36
32;37

Maternal
Repeat Size

Paternal
Repeat Size

29;58

29

32;149

36

31;99

Needs
Testing

32;37
>200
>200

DISCUSSION
In this study, the development and validation of a method to detect FX CGG
repeats within the FMR1 gene of embryo TE biopsies has progressed remarkably for
reproductive competence within IVF patients seeking SGD testing for FXS. Proper
validation began with the use of gDNA from samples with known repeat sizes. The
gDNA was isolated from different sample types; such as blood, buccal swabs, and villi. It
was determined that gDNA isolated from multiple samples types can undergo this
methodology and will produce desirable results.
Finding an amplification method is necessary in this study because the small input
of DNA provided from the limited number of cells in a TE biopsy cannot be detected
without it. Four different amplification methods were tested to amplify the minute
amounts of initial DNA. The first method, using the GenomePlex WGA4 Amplification
kit, did not produce any results when the CE was run. No peaks were detected during the

57

analysis because the GenomePlex WGA4 amplification method involves random primer
annealing. It is uncontrollable which region gets amplified. Additionally, there is only
about a 60% coverage for WGA products and allele drop out is bound to occur. The
amplicon produced by WGA is only around 400-500 base pairs; therefore, if the FMR1
amplicon falls outside this range it will not be detected by the CE. Because the FMR1
amplicon can consist of over 200 CGG repeats at times, the expected amplicon would be
over 600 base pairs which would not work for this particular method. The same scenario
occur for method number 2 using the SurePlex DNA Amplification system. No peaks
were detected using the method as well for similar reasons as previously discussed.
The next tested method involved a targeted pre-amplification of the FMR1 gene
with uniquely made primers. A lot of trouble shooting occurred for this methodology.
Validation tests needed to be done to ensure the primers were outside the desired
amplicon region before beginning. NGS was one of those validation steps and figure 5A
and 5B confirm that our FMR1 primer is outside the FMR1 region. However, the signal
intensity of the peak is very low, unlike the signal intensity for peaks of gDNA.
Additionally, multiple tests needed to be run to determine how many cycles were
necessary for this pre-amplification step. It took 42 cycles for a peak to be detected after
running the CE. Nevertheless, a peak was detected only once for the practice samples of
the aneuploid control cell line 1359. Use of this kit was attempted on the samples picked
from the FX cell lines. It resulted in the presence of too many peaks being displayed. This
could be the result of too much amplification, contamination, or the presence of more
than 6 cells initally. It was disappointing this method did not produce desirable results
because this protocol is done concurrently with the present CCS method for embryo TE
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biopsies. Therefore, no additional biopsies will be needed from embryos that elect to
undergo SGD testing for FXS.
Lastly, the REPLI-g Single Cell Kit for amplification was tested. Although this
method is also a WGA method, it is additionally an MDA method. MDA methods are
very effective when the production of long fragments is necessary. Each enzyme remains
bound and continues replication of a single template for up to 1,000 kilo bases. The
specific enzyme used is Phi29 DNA polymerase, which has very low error rates due to its
1000 fold higher fidelity than taqDNA polymerase. There are fewer enzyme binding
events; therefore, less opportunities for certain templates to be over or under-represented.
The high affinity for use on small starting material and good processing is necessary for
generating the longer fragments. There are also only 1-2 steps during the preparation of
the library, which reduces the chance DNA loss by having too many intermediate steps.
The REPLI-g Single Cell Kit for amplification produced desirable results, as seen in
figure 4. For extra confirmation of the ability of this method, 48 samples were collected
and de-identified. Knowing which cell line each sample came from causes some bias
when conducting the data analysis. Blinding the samples helps remove that bias from the
study. This method was chosen to advance onto phase 3 to see if it could work on more
realistic samples; such as arrested embryos and biopsies of whole embryos.
To begin phase 3, additional tests were conducted to ensure the single cell lysis
method works concordantly with the REPLI-g amplification method. After many test
runs, it was observed that it worked accurately. These tests were done because the
arrested embryos used in this phase were already lysed using that method. Unfortunately,
because the embryos arrested before the blastocyst stage, there was no PGD for FX
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conducted. Therefore, when the testing for this project occurred, there was no way to
confirm our results. However, the parental repeat sizes were determined and used to
observe which allele was inherited by each embryo. 10 out of the 12 arrested embryos
used produced good results after going through the developed methodology. The 2
samples that did not work produced no signal when undergoing the CE. After conducting
the genotyping for gender and observing embryo quality, there were no commonalities
between the 2 samples that did not produce any signal.
Whole embryos were then biopsied to provide this project with the most realistic
sample type to test the methodology. 2 replicates from each of the 5 biopsied aneuploid
whole embryos were used to confirm the use of this methodology on clinical samples.
Because these samples are discarded aneuploid whole embryos, they underwent PGD.
The standard CCS method used for these embryos was PCR24, a qPCR based method of
CCS for aneuploidy screening. Currently, the standard method for CCS testing changed
to NexCCS, a NGS based method. A comparison was done to observe the differences
between the 2 methods, seen in table 6. Fortunately for this clinic, the current method of
CCS using NexCCS is the more sensitive method. After review of the FX results for the
biopsies, in figure 12, the correct number of peaks and repeat sizes were determined for
each of the samples. It gave great confidence that this method may be clinically
implemented in the future.
Overall, there were many validation and preparatory steps taken to ensure this
methodology works accurately. Further investigation of validating this platform could
involve de-identifying the discarded aneuploid whole embryo biopsies to confirm the
CGG repeat sizes and the sensitivity of the developed method. More experiments with a
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larger sample size are necessary before transitioning this methodology to be clinically
implemented.
The developed method can aid female patients who seek IVF treatment for SGD
testing of FX in many different ways. Women who inherited a premutation FX allele are
at risk for FXPOI and can benefit greatly by this new method. These patients may have
difficulty reproducing because of FXPOI; but, using this method they can ensure that
their affected allele does not get transmitted to their offspring. Similarly, confirming no
expansion has occurred if the affected allele was transmitted. Another way this method
benefits female patients is if they are of advanced maternal age. Women of advanced
maternal age also have difficulty reproducing because they may not have the ability
produce embryos that survive through to the blastocyst stage. There is a higher rate of
aneuploidy that is present in the eggs of women of advanced maternal age. Now, factor in
the chance that these older women also have a premutation FMR1 allele. They would not
be able to produce many embryos; while also needing to worry about transmitting their
affected FMR1 allele to their offspring. If a woman is a carrier of a premutation FMR1
allele has two embryos available for transfer, where one is euploid but inherited her FX
affected allele and the other is aneuploid, this newly developed test can help. Instead of
discarding the euploid embryo just because it inherited the affected X chromosome, this
new test can determine the exact number of CGG repeats present on that affected X
chromosome. Therefore, if little to no expansion occurred that embryo could be a
candidate to be transferred and save the embryo from being discarded.
Physicians can also benefit from this developed method because they can provide
similar patients with proper counseling needed to go through the strenuous process of
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IVF. Transferring embryos with FMR1 premutation alleles will encompass more diligent
genetic counseling and detailed consents. This newly developed method to detect FX
CGG repeats within the FMR1 gene of embryo TE biopsies can help save many embryos
that may be suitable for transfer from being discarded; while simultaneously further the
field of reproductive competence.
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